CYTK Cytokinetics, Incorporated - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 6, 2026
$65,60
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$54,30rendah 52m
$88,31tinggi 52m
Kapitalisasi Pasar
$8.07B
P/E (TTM)
-9.1
EPS (TTM)
$-7.23
Pendapatan (TTM)
$68M
lencana Anda
Rentang 52M
$54–$88
Peringkat Analis
BUY
Target Harga
$110
P/E
-9.1
ROE
329.8%
Margin Laba Bersih
-1321.1%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
CYTK Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$65.60
Kapitalisasi Pasar
$8.07B
P/E (TTM)
-9.1
EPS (TTM)
$-7.23
Pendapatan (TTM)
$68M
ROE (TTM)
329.8%
D/E Utang/Ekuitas (MRQ)
-1.6
Rentang 52M
$54–$88
CYTK Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 25 Juni 2013 | 1-for-6 | Terbalik |
Tentang Cytokinetics, Incorporated - Common Stock Tinjauan perusahaan dari Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan673
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$88M2016-12-31 → 2025-12-31
EPS$-6.542016-12-31 → 2025-12-31
Arus Kas Bebas$-535M2016-12-31 → 2025-12-31
Margin bersih-1321.1%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | CYTK | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -9.1rata-rata 5T ≈-12.2 | ≈-12.2 | · | · | |
| P/S | 91.6rata-rata 5T ≈323.5 | ≈323.5 | 41.9 | Terlalu mahal | |
| P/B | -12.2rata-rata 5T ≈-19.9 | ≈-19.9 | · | · | |
| EV / EBITDA | -13.7rata-rata 5T ≈-15.1 | ≈-15.1 | · | · | |
| Price / FCF (Harga / FCF) | -15.1rata-rata 5T ≈-16.6 | ≈-16.6 | · | · | |
| Price / Cash Flow (Harga / Arus Kas) | -15.8rata-rata 5T ≈-18.3 | ≈-18.3 | · | · | |
| EV / Revenue (EV / Pendapatan) | 93.5rata-rata 5T ≈322.6 | ≈322.6 | · | · | |
| EV / FCF | -15.4rata-rata 5T ≈-16.6 | ≈-16.6 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | CYTK | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -1046.1%rata-rata 5T ≈-2159.0% | ≈-2159.0% | -118.4% | Lemah | |
| Margin EBITDA (TTM) | -1027.6%rata-rata 5T ≈-2113.0% | ≈-2113.0% | -118.4% | Lemah | |
| Margin Laba Bersih (TTM) | -1321.1%rata-rata 5T ≈-2357.7% | ≈-2357.7% | -176.2% | Lemah | |
| ROA (TTM) | -56.8%rata-rata 5T ≈-47.8% | ≈-47.8% | -22.9% | Lemah | |
| ROE (TTM) | 329.8%rata-rata 5T ≈322.1% | ≈322.1% | -13.2% | Tingkat teratas |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | CYTK | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | -1.6rata-rata 5T ≈-0.4 | ≈-0.4 | 0.3 | Utang rendah | |
| Rasio Lancar (MRQ) | 6.7rata-rata 5T ≈6.7 | ≈6.7 | 5.9 | Sejajar | |
| Quick Ratio (Rasio Cepat) | 0.7rata-rata 5T ≈1.1 | ≈1.1 | 3.6 | Likuiditas rendah | |
| Utang Jangka Panjang / Ekuitas (MRQ) | -1.4rata-rata 5T ≈-0.3 | ≈-0.3 | · | · | |
| Interest Coverage (Cakupan Bunga) | -13.4rata-rata 5T ≈-14.6 | ≈-14.6 | -7.7 | Likuiditas rendah |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | CYTK | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 376.6%rata-rata 5T ≈98.1% | ≈98.1% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | -2.4%rata-rata 5T ≈-29.0% | ≈-29.0% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 9.5% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | CYTK | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.1rata-rata 5T ≈0.1 | ≈0.1 | 0.2 | Lemah | |
| Receivables Turnover (Perputaran Piutang) | 5.1rata-rata 5T ≈4.8 | ≈4.8 | 5.7 | Sejajar | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$130.8K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-4.4%
Laporan Berikutnya
Nov 03, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 5, 2026 | $-1.50 | $-1.67 | 10.4% |
| 31 Maret 2026 | $-1.67 | $-1.69 | 0.94% | |
| 31 Des. 2025 | $-1.50 | $-1.49 | -0.97% | |
| 30 Sep. 2025 | $-2.55 | $-1.61 | -58.2% | |
| 30 Juni 2025 | $-1.12 | $-1.41 | 20.3% | |
| 31 Maret 2025 | $-1.39 | $-1.41 | 1.4% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-5.37 | $-1.15 | $-3.80 | $-1.14 | $2.88 | $1.60 | $-0.18 | $0.47 | $2.04 | $2.32 | $1.73 | $2.38 | |
| Revenue / Share | $733.03 | $164.98 | $78.01 | $1053.03 | · | · | · | · | $0.27 | $2.50 | · | · | |
| Cash Flow / Share | $-4246.43 | $-3535.39 | $-4292.54 | $-3334.44 | · | · | · | · | $-2.06 | $0.87 | · | · | |
| Cash / Share | $1.00 | $0.80 | $1.11 | $0.69 | $1.33 | $1.17 | $0.62 | $0.77 | $2.32 | $1.65 | $1.64 | $0.52 | |
| EPS (TTM) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $216.71 | $157.01 | · | $16.14 | $558.94 | $13.33 | · | $3.93 | $2.28 | $8.19 | · | $3.93 | $9.05 | $48.47 | · | $26.82 | |
| Cash Flow / Share | · | $-1179.96 | · | · | · | $-1110.73 | · | · | · | $-1270.62 | · | · | · | $-1285.00 | · | · | |
| EPS (TTM) | $-7.23 | $-6.85 | · | $-6.29 | $-5.10 | $-5.29 | · | $-5.38 | $-5.37 | $-5.40 | · | $-5.60 | $-5.77 | $-4.66 | · | $-3.12 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $106M | · | $87M | $86M | $19M | · | $3M | $3M | $4M | · | $8M | $10M | $98M | · | $148M | |
| Net Income TTM | $-894M | $-830M | · | $-752M | $-606M | $-615M | · | $-576M | $-545M | $-531M | · | $-527M | $-540M | $-431M | · | $-282M | |
| P/E | -11.8 | -9.6 | · | -8.7 | -6.5 | -7.6 | · | -9.8 | -10.1 | -13.0 | · | -5.3 | -5.7 | -7.6 | · | -15.5 | |
| Earnings Yield | -8.5% | -10.4% | · | -11.4% | -15.4% | -13.2% | · | -10.2% | -9.9% | -7.7% | · | -19.0% | -17.7% | -13.2% | · | -6.4% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $88M | $18M | $8M | $95M | $70M |
| Margin Operasi % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Laba Bersih | $-785M | $-590M | $-526M | $-389M | $-215M |
| EPS Dilusian | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Rasio Lancar | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Rasio Cepat | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-535M | $-400M | $-416M | $-311M | $-191M |
Pemilik institusional (13F) 535 pengaju · $13.2B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
535
Nilai yang dipegang
$13.2B
Posisi baru
95
Posisi yang keluar
49
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 95 (-11 vs Kuartal sebelumnya) | 49 (-7 vs Kuartal sebelumnya) | 238 (+49 vs Kuartal sebelumnya) | 113 (-29 vs Kuartal sebelumnya) | +10.8M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| BlackRock, Inc. | $1.711.838.738 | 20.094.362 | 12,99% | Saham |
| VANGUARD GROUP INC | $765.538.243 | 12.048.131 | 5,81% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $590.517.486 | 6.931.770 | 4,48% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.778.157 | 6.711.799 | 4,34% | Saham |
| STATE STREET CORP | $553.243.709 | 6.494.233 | 4,20% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.151.103 | 6.117.515 | 3,95% | Saham |
| FMR LLC | $428.657.534 | 5.031.782 | 3,25% | Saham |
| Avoro Capital Advisors LLC | $425.949.915 | 4.999.999 | 3,23% | Saham |
| BANK OF AMERICA CORP /DE/ | $394.916.049 | 4.635.709 | 3,00% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $316.325.896 | 3.712.501 | 2,40% | Saham |
| RTW INVESTMENTS, LP | $243.814.036 | 2.862.003 | 1,85% | Saham |
| Polar Capital Holdings Plc | $191.988.358 | 2.253.649 | 1,46% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161.060.214 | 1.890.600 | 1,22% | Opsi beli |
| GOLDMAN SACHS GROUP INC | $150.069.725 | 1.761.588 | 1,14% | Saham |
| Capital Research Global Investors | $143.683.584 | 1.686.625 | 1,09% | Saham |
| NORTHERN TRUST CORP | $140.337.319 | 1.647.345 | 1,06% | Saham |
| JPMORGAN CHASE & CO | $139.150.046 | 1.588.895 | 1,06% | Saham |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136.597.224 | 1.603.442 | 1,04% | Saham |
| Integral Health Asset Management, LLC | $136.304.000 | 1.600.000 | 1,03% | Saham |
| Point72 Asset Management, L.P. | $135.257.185 | 1.587.712 | 1,03% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133.388.883 | 1.565.781 | 1,01% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131.998.327 | 1.549.458 | 1,00% | Saham |
| ARMISTICE CAPITAL, LLC | $130.340.700 | 1.530.000 | 0,99% | Opsi beli |
| MORGAN STANLEY | $128.664.004 | 1.510.318 | 0,98% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $111.740.656 | 1.311.664 | 0,85% | Saham |
| Capital International Investors | $111.245.191 | 1.305.848 | 0,84% | Saham |
| Invesco Ltd. | $105.237.167 | 1.235.323 | 0,80% | Saham |
| ARMISTICE CAPITAL, LLC | $102.342.325 | 1.201.342 | 0,78% | Saham |
| UBS Group AG | $99.781.940 | 1.171.287 | 0,76% | Saham |
| Pictet Asset Management Holding SA | $99.038.455 | 1.160.463 | 0,75% | Saham |
| Frazier Life Sciences Management, L.P. | $98.810.092 | 1.159.879 | 0,75% | Saham |
| Bank of New York Mellon Corp | $98.027.901 | 1.150.697 | 0,74% | Saham |
| Holocene Advisors, LP | $97.506.685 | 1.144.579 | 0,74% | Saham |
| Woodline Partners LP | $93.769.315 | 1.100.708 | 0,71% | Saham |
| D. E. Shaw & Co., Inc. | $89.287.894 | 1.048.103 | 0,68% | Saham |
| NORGES BANK | $86.512.319 | 1.015.522 | 0,66% | Saham |
| Royalty Pharma Sub-Manager, LLC | $83.519.594 | 980.392 | 0,63% | Saham |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81.937.000 | 961.815 | 0,62% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $77.218.175 | 906.423 | 0,59% | Saham |
| CITADEL ADVISORS LLC | $77.062.874 | 904.600 | 0,58% | Opsi beli |
| FRANKLIN RESOURCES INC | $75.911.721 | 891.087 | 0,58% | Saham |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $70.521.134 | 827.810 | 0,53% | Saham |
| Melqart Asset Management (UK) Ltd | $65.385.455 | 767.525 | 0,50% | Saham |
| Siren, L.L.C. | $64.655.121 | 758.952 | 0,49% | Saham |
| Fisher Asset Management, LLC | $63.355.547 | 743.697 | 0,48% | Saham |
| Foresite Capital Management IV, LLC | $60.884.867 | 714.695 | 0,46% | Saham |
| Balyasny Asset Management L.P. | $60.599.821 | 711.349 | 0,46% | Saham |
| Deep Track Capital, LP | $59.633.000 | 700.000 | 0,45% | Saham |
| JANE STREET GROUP, LLC | $59.633.000 | 700.000 | 0,45% | Opsi beli |
| BNP PARIBAS FINANCIAL MARKETS | $58.702.470 | 689.077 | 0,45% | Saham |
Orang dalam perusahaan 52 orang dalam · 19 pejabat · 23 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Robert I Blum | President & CEO | 28 Sep. 2026 M | 278.544 | 0 | 20 | $-17.291.957 |
| Sung Lee | EVP, Chief Financial Officer | 1 Juli 2026 M | 63.221 | 0 | 5 | $-5.695.855 |
| Ching Jaw | SVP Finance & CFO | 6 Maret 2023 A | 87.346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 Feb. 2017 F | 40.323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 22 Sep. 2026 M | 153.902 | 0 | 21 | $-4.654.735 |
| Andrew Callos | EVP, Chief Commercial Officer | 31 Agu 2026 M | 58.555 | 0 | 25 | $-16.021.293 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 Maret 2026 A | 107.943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 Des. 2024 A | 18.655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 Agu 2024 A | 33.140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 Maret 2022 M | 103.408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 Maret 2022 F | 153.233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 Feb. 2018 A | 32.548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 Feb. 2018 A | 21.520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 Agu 2017 M | 46.441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 Feb. 2017 A | 29.004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 Feb. 2017 A | 47.255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 Feb. 2011 A | 42.000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 Des. 2009 M | 20.043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 Feb. 2008 A | 47.896 | 0 | 0 | $0 |
| Robert E Landry | Direktur | 15 Sep. 2026 S | 8.184 | 0 | 2 | $-146.790 |
| Lynne B Parshall | Direktur | 1 Sep. 2026 S | 10.784 | 0 | 4 | $-1.357.500 |
| Robert Arthur Harrington | Direktur | 15 Juli 2026 A | 21.932 | 0 | 1 | $-143.620 |
| James M Daly | Direktur | 15 Juli 2026 A | 3.390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Direktur | 15 Juli 2026 A | 10.434 | 0 | 4 | $-2.837.811 |
| Nancy Wysenski | Direktur | 15 Juli 2026 A | 33.992 | 0 | 0 | $0 |
| Wendell Wierenga | Direktur | 15 Juli 2026 A | 35.563 | 0 | 3 | $-1.881.925 |
| John T Henderson | Direktur | 15 Juli 2026 A | 78.360 | 0 | 2 | $-2.078.525 |
| Muna Bhanji | Direktur | 27 Mei 2026 A | 26.361 | 0 | 0 | $0 |
| Wendall Wierenga | Direktur | 15 Juli 2025 A | 32.345 | 0 | 0 | $0 |
| COSTA SANTO J | Direktur | 15 Mei 2024 A | 20.600 | 0 | 0 | $0 |
| Sandford D Smith | Direktur | 2 Jan. 2024 A | 18.801 | 0 | 0 | $0 |
| Robert Califf | Direktur | 3 Jan. 2022 A | 6.003 | 0 | 0 | $0 |
| GAGE L PATRICK | Direktur | 8 Nov. 2021 M | 28.932 | 0 | 0 | $0 |
| Denise Gilbert | Direktur | 20 Mei 2015 J | · | 0 | 0 | $0 |
| Stephen M Dow | Direktur | 2 Jan. 2013 A | 1.421.052 | 0 | 0 | $0 |
| James A Spudich | Direktur | 18 Mei 2011 A | 180.600 | 0 | 0 | $0 |
| Grant A Heidrich III | Direktur | 3 Jan. 2011 A | 93.755 | 0 | 0 | $0 |
| Michael Schmertzler | Direktur | 3 Juni 2010 S | 4.340.923 | 0 | 0 | $0 |
| Mark Mcdade | Direktur | 21 Mei 2009 A | · | 0 | 0 | $0 |
| Charles J Homcy | Direktur | 22 Mei 2008 A | · | 0 | 0 | $0 |
| William J Rutter | Direktur | 29 April 2004 C | 172.413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Pemilik 10% | 29 April 2004 C | 1.615.716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Pemilik 10% | 29 April 2004 C | 771.052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Pemilik 10% | 29 April 2004 C | 650.000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Pemilik 10% | 29 April 2004 C | 755.631 | 0 | 0 | $0 |
| Elisabeth Schnieders | · | 28 Feb. 2017 A | 43.919 | 0 | 0 | $0 |
| James H Sabry | · | 3 Juni 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | · | 29 April 2004 C | 24.050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | · | 29 April 2004 C | 625.950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | · | 29 April 2004 C | 1.742.951 | 0 | 0 | $0 |
| SEVIN ROSEN VIII AFFILIATES FUND LP | · | 29 April 2004 C | 15.421 | 0 | 0 | $0 |
| SEVIN ROSEN VI AFFILIATES FUND LP | · | 29 April 2004 C | 127.235 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 54 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,51% | 19.346 NS | 31 Juli 2026 | N-PORT |
| XMMO · Invesco Exchange-Traded Fund Trust | 0,81% | 882.597 SH | 2 Okt. 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,79% | 50.312 NS | 31 Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,73% | 1.020.305 SH | 11 Sep. 2026 | Harian |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,72% | 53.872 NS | 31 Juli 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,64% | 107.023 NS | 31 Juli 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102.933 SH | 19 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,61% | 9.831 SH | 2 Okt. 2026 | Harian |
| IQSM · New York Life Investments ETF Trust | 0,35% | 14.748 NS | 31 Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761.130 SH | 19 Agu 2026 | Harian |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72.343 SH | 19 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,33% | 63.327 NS | 31 Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1.797.986 SH | 19 Agu 2026 | Harian |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219.413 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,32% | 3.378.753 SH | 11 Sep. 2026 | Harian |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53.623 SH | 19 Agu 2026 | Harian |
| ISCG · iShares Trust | 0,30% | 39.366 SH | 11 Sep. 2026 | Harian |
| PTMC · Pacer Funds Trust | 0,29% | 14.892 NS | 31 Juli 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,27% | 48.364 NS | 31 Juli 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,24% | 20.179 NS | 31 Juli 2026 | N-PORT |
| ESML · iShares Trust | 0,23% | 88.671 SH | 11 Sep. 2026 | Harian |
| MIDU · Direxion Shares ETF Trust | 0,22% | 1.994 NS | 31 Juli 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,22% | 687 NS | 31 Juli 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,22% | 16.176 NS | 31 Juli 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 54.306 NS | 31 Juli 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,20% | 15.469 NS | 31 Juli 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3.254 NS | 31 Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40.586 SH | 19 Agu 2026 | Harian |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3.113.794 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,14% | 333.056 SH | 19 Agu 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,13% | 1.557.779 SH | 19 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,12% | 52.671 NS | 31 Juli 2026 | N-PORT |
| ESSC · Strategy Shares | 0,10% | 466 NS | 31 Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,09% | 7.841 SH | 11 Sep. 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 15.233 SH | 19 Agu 2026 | Harian |
| IWO · iShares Trust | 0,07% | 133.196 SH | 11 Sep. 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 27.265 SH | 2 Okt. 2026 | Harian |
| TILT · FlexShares Trust | 0,02% | 5.740 NS | 31 Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 4.315.260 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 10.880 SH | 19 Agu 2026 | Harian |
| ESGV · VANGUARD WORLD FUND | 0,02% | 29.174 SH | 19 Agu 2026 | Harian |
| IUSG · iShares Trust | 0,01% | 64.511 SH | 11 Sep. 2026 | Harian |
| IUSV · iShares Trust | 0,01% | 53.197 SH | 11 Sep. 2026 | Harian |
| ITOT · iShares Trust | 0,01% | 180.021 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,01% | 36.083 SH | 10 Sep. 2026 | Harian |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 106.638 SH | 19 Agu 2026 | Harian |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,00% | 478 SH | 29 Sep. 2026 | Harian |
| IJH · iShares Trust | · | 4.763.860 SH | 11 Sep. 2026 | Harian |
| IJK · iShares Trust | · | 425.186 SH | 11 Sep. 2026 | Harian |
| IJJ · iShares Trust | · | 318.457 SH | 21 Agu 2026 | Harian |
| IWN · iShares Trust | · | 1.107.696 SH | 11 Sep. 2026 | Harian |
| XJH · iShares Trust | · | 18.548 SH | 8 Sep. 2026 | Harian |
| ISCB · iShares Trust | · | 5.565 SH | 11 Sep. 2026 | Harian |
| SMLF · iShares Trust | · | 71.881 SH | 11 Sep. 2026 | Harian |
CYTK Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 28 analis
BELI
Target median
$107.50
+63,9%
6 21,4%
Beli Kuat
19 67,9%
Beli
3 10,7%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
20 analis · 2026-09-29Target rata-rata $109.90 +67,5%
← Di bawah semua target
Harga saat ini $65.60
Rendah$85.00
Rata-rata$109.90
Tinggi$146.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 6, 2026